Abstract:1086 Objectives: In this study, arginine-arginine-leucine (RRL) a tumor targeting peptide is designed to link the bifunctional chelator mercaptoacetyltriglycine (MAG3), aiming to explore the labeling conditions of Tc-99m and to evaluate the imaging of this probe in vivo. Methods: Tc-99m was labeled through the SnCl2 reduction method, and the main factors affecting the labeling were investigated respectively to obtain the suitable labeling conditions. The paper chromatography was used to determine the labeling rate and radiochemical purity. Cysteine replacement experiment and incubation experiment of normal saline/bovine serum albumin was utilized to evaluate the stability of Tc-99m-MAG3-RRL in vitro. HepG2 tumor-bearing models were established and after tail vein injection, gamma camera imaging and biodistribution study were respectively performed periodically. Results: The purity of MAG3-RRL was 98.94%. Under the suitable labeling conditions, the labeling rate was 93.67% ± 1.10%, and the radiochemical purity was 94.32% ± 0.19% (n=3). Tc-99m-MAG3-RRL was placed in normal saline at room temperature and 50% BSA at 37 ℃, the radiochemical purity of Tc-99m-MAG3-RRL was more than 90% (n=3) within 6 hours. The highest replacement rate of Tc-99m-MAG3-RRL was 0.57% ± 0.21% in cysteine solution, and 0.41% ± 0.04% in normal saline control (n=3, P>0.05). The distribution coefficient IgP of Tc-99m-MAG3-RRL was -0.15 ± 0.01 (n=3). Gamma camera imaging revealed substantial uptake of Tc-99m-MAG3-RRL in tumors. The specific uptake of Tc-99m-MAG3-RRL in tumor was significantly higher than that of control test after injection (P<0.05). In planar gamma imaging study, the tumors were imaged clearly at 2-4h after injection of Tc-99m-MAG3-RRL, with the highest tumor-to-muscle ratio 5.63 ± 0.40 in 30min. Biodistribution data showed that Tc-99m-MAG3-RRL was rapidly accumulated in tumor within 30min with the highest tumor-to-muscle ratio 5.50 ± 0.74. And then it was rapidly cleared from the blood and predominantly accumulated in the kidneys. Conclusions: The results show that MAG3 could successfully be connected to RRL polypeptide and further improve the labeling rate, and the preparation method of Tc-99m-MAG3-RRL is simple and fast. Tc-99m-MAG3-RRL probe has good stability in vitro. Animal study shows that Tc-99m-MAG3-RRL can be used as a potential candidate for visualization of malignant carcinomas. Keywords: Arginine-Arginine-Leucine; Tc-99m; MAG3

Technetium-99m- Arg-Arg-Leu(g2), a Modified Peptide Probe Targeted to Neovascularization in Molecular Tumor Imaging.

Use of Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovasculari- Zation As Well As Tumor Cells in Molecular Tumor Imaging.

The Further Study on Radioiodinated Peptide Arg-Arg-Leu Targeted to Neovascularization As Well As Tumor Cells in Molecular Tumor Imaging

188Re-Labeled GX1 Dimer As a Novel Dual-Functional Probe Targeting TGM2 for Imaging and Antiangiogenic Therapy of Gastric Cancer

A Novel Tc-99m-Labeled Molecular Probe For Tumor Angiogenesis Imaging In Hepatoma Xenografts Model: A Pilot Study

Study of Novel Peptide Probe 131 I-RRL for Tumor Molecular Imaging

A novel radioiodinated peptide of arginine-arginine-leucine(RRL)for biodistribution and tumor angiogenic endothelium imaging

A Novel 99mTc-Labeled Molecular Probe for Tumor Angiogenesis Imaging in Hepatoma Xenografts Model:A Preliminary Study

One-step Radiosynthesis of 18F-Alf-nota-rgd2 for Tumor Angiogenesis PET Imaging

131)I Labeling and Bioactivity Evaluation of a Novel RGD Dimer Targeted to Integrin Αvβ3 Receptor

A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging

Detection of Pulmonary Metastases with the Novel Radiolabeled Molecular Probe, (99M)tc-Rrl.

Improving Tumor Uptake and Pharmacokinetics of (64)Cu-Labeled Cyclic RGD Peptide Dimers with Gly(3) and PEG(4) Linkers.

A Novel Tc-99m-labeled and MAG<sub>3</sub>-chelated Arginine-Arginine-Leucine containing Peptide for Tumor Imaging in Hepatoma Xenografts Model

Improving Tumor Uptake and Excretion Kinetics of 99Mtc-Labeled Cyclic Arginine-Glycine-aspartic (RGD) Dimers with Triglycine Linkers.

[99mTc]-labeling and evaluation of a new linear peptide for imaging of glioblastoma as a αvβ3-positive tumor

99Mtc-Labeled RGD-BBN Peptide for Small-Animal SPECT/CT of Lung Carcinoma.

A radiofluorinated divalent cystine knot peptide for tumor PET imaging.

Radiolabeled Cyclic RGD Peptides As Radiotracers for Tumor Imaging.

Preliminary Clinical Application of RGD-Containing Peptides as PET Radiotracers for Imaging Tumors

99m TcO(MAG 2 -3G 3 -dimer): a new integrin α v β 3 -targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics